Results 171 to 180 of about 53,983 (298)

Proximity Proteomics Maps Candidate Cellular Uptake Pathways for Cell‐Derived Nanovesicles

Small Methods, EarlyView.
TurboID‐based dual‐sided proteomics compares mechanically generated cell‐derived nanovesicles with naturally secreted small extracellular vesicles. Vesicle proteomes define candidate interaction signatures, while recipient‐cell proximity labelling identifies exposure‐associated proteins.
Eisuke Kanao, Ryosuke Mizuta, Saki Tarao, Yukika Hara, Yuka Li, Kazunari Akiyoshi, Yasushi Ishihama, Koshi Imami, Yoshihiro Sasaki   +8 more
wiley   +1 more source

Identification of MEF2A, MEF2C, and MEF2D interactomes in basal and Fsk‐stimulated mouse MA‐10 Leydig cells

Andrology, EarlyView.
Abstract Background Myocyte enhancer factor 2 transcription factors regulate essential transcriptional programs in various cell types. The activity of myocyte enhancer factor 2 factors is modulated through interactions with cofactors, chromatin remodelers, and other regulatory proteins, which are dependent on cell context and physiological state.
Karine de Mattos, Marie‐Pier Scott‐Boyer, Arnaud Droit, Robert S. Viger, Jacques J. Tremblay   +4 more
wiley   +1 more source

Target-biology and interactome-derived signatures predict target-level associations with safety-related drug attrition. [PDF]

Sci Rep
Breffle J, Jones A, Ghiassian SD.
europepmc   +1 more source

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

Brain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero‐Murillo, Djordje Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría   +7 more
wiley   +1 more source

High-Precision Intrinsic Interactome Elucidation of Chimeric Antigen Receptors via Photocatalytic Micromapping (μMap-CAR). [PDF]

J Am Chem Soc
Huth SW, Pan CR, Raftopoulos P, Seath CP, Lovett GH, Li B, Yechan Gunja S, Agarwal V, Amako Y, Bell-Temin H, Pham H, Evans H, Qiao JX, Liu H, Barajas B, MacMillan DWC.   +15 more
europepmc   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Individualized Interactomes From Pulmonary Arterial Hypertension Cell Biopsies Inform Pharmacotherapeutic Response. [PDF]

JACC Basic Transl Sci
Wang RS, Singh N, Wathieu H, Baird G, Cox-Flaherty K, Klinger JR, Mullin CJ, Pereira M, Whittenhall M, Harrington EO, Maron BA, Ventetuolo CE.   +11 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Decoding the gut interactome after severe trauma: from molecular dialogue to integrative treatment strategies. [PDF]

Front Microbiol
Huang H, Yang M, Tan L, Fu Z.
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source